SCHEMBL18825438

SCHEMBL18825438

CCc1cnc(N2CCC(COc3ccc(C4=CCC(C(=O)N5CCSCC5)CC4)cc3F)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 16/20 0.47
▸ KCNH2 Q12809 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ CHRM4 P08173 1/20 0.34
▸ MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18825519 0.93 GPR119 (0.48) GPR119KCNH2FFAR4MGLL
SCHEMBL18825503 0.93 GPR119 (0.48) GPR119KCNH2FFAR4MGLL
SCHEMBL18825334 0.92 GPR119 (0.48) GPR119KCNH2FFAR4MGLL
SCHEMBL18825326 0.92 GPR119 (0.47) GPR119KCNH2FFAR4MGLL
SCHEMBL18825412 0.92 GPR119 (0.49) GPR119KCNH2FFAR4MGLL
SCHEMBL18825473 0.92 GPR119 (0.42) GPR119KCNH2NPC1ALDH1A1
SCHEMBL18825411 0.92 GPR119 (0.47) GPR119KCNH2FFAR4MGLL
SCHEMBL18825375 0.91 GPR119 (0.47) GPR119KCNH2MEN1NPC1RAB9A
SCHEMBL18825421 0.91 GPR119 (0.47) GPR119KCNH2FFAR4MGLL
SCHEMBL18825446 0.91 GPR119 (0.47) GPR119KCNH2NPC1RAB9AFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US claimed
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2018-11-08 — — US claimed
EP-3352750-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT Hyundai Pharm Co., Ltd. (KR) 2018-08-01 — — EP claimed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO claimed
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US disclosed
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US disclosed
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2018-11-08 — — US disclosed
EP-3352750-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT Hyundai Pharm Co., Ltd. (KR) 2018-08-01 — — EP disclosed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO disclosed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 1981/4885MEN1 619/4885
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 1981/4885MEN1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback